Mikael Dolsten
Senior Vice President & President, Worldwide Research & Development

Dr. Mikael Dolsten is the President of Worldwide Research and Development, advancing Pfizer's leadership in small molecule science and medicines, as well as its leadership, expertise, and innovation in the areas of biotherapeutics and vaccines. Worldwide R&D combines entrepreneurial Biotech Units with core platforms; Research Units with deep disease area expertise; and broad multi disciplinary scientific expertise to discover innovative therapeutic programs in biotherapeutics, vaccines and small molecules.

Industry-leading technology, clinical, and biological platform disciplines efficiently advance programs into clinical development, successful proof-of-concept studies, and the eventual launch of new high impact medicines by Pfizer business units. Additionally, expertise in Drug Safety, Development Operations, and both small- and large-molecule Pharmaceutical Sciences enables the delivery of Pfizer's entire portfolio.

Previously, Dolsten, who is a physician, was Senior Vice President, Wyeth Inc., and President of Wyeth Research where he led a global organization of some 6,000 staff throughout the U.S., Europe and Asia focused on the research and development of small molecules, vaccines and protein-based medicines in therapy areas including inflammation, women's health, neuroscience, oncology, infectious diseases (vaccines, antibiotics), hemophilia, gastrointestinal and musculoskeletal diseases. He was also a member of the Management, Operations, Human Resources/Benefits and the Law and Regulatory Committees of Wyeth Pharmaceuticals.

Before joining Wyeth, Dolsten served as Executive Vice President within Pharmaceutical Research & Development/Medicine at Boehringer Ingelheim. He was responsible for leading the company's worldwide pharmaceutical research in the U.S., Canada, Germany, Italy, Austria and Japan - with major programs in seven therapeutic areas, including respiratory, inflammation/immunology, oncology, virology, cardiovascular, metabolism and central nervous system. In addition, he was a member of the corporate management team responsible for reviewing all worldwide development projects and licensing opportunities.

Prior to joining Boehringer Ingelheim, Dolsten spent more than 15 years in leadership roles in pharmaceutical research, including positions with AstraZeneca (respiratory, immunology, cardiovascular, metabolism, gastrointestinal) and Pharmacia & Upjohn (oncology, immunology).

Dolsten earned his Ph.D. in tumor immunology and M.D. from the Medical Faculty, University of Lund in Sweden. He also studied virology and cell biology at the Weizmann Institute in Israel and has been appointed as Adjunct Professor in Immunology at the Medical Faculty in Lund. In addition, he is a Fellow of The New York Academy of Medicine (NYAM) and a Governor of the New York Academy of Sciences.

Dolsten has published several patents and approximately 150 articles in international journals.